Spear Matthew A. 4
4 · Poseida Therapeutics, Inc. · Filed Aug 24, 2021
Insider Transaction Report
Form 4
Spear Matthew A.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-20$1.32/sh+4,000$5,288→ 45,485 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-08-20−4,000→ 90,861 totalExercise: $1.32Exp: 2026-06-19→ Common Stock (4,000 underlying) - Sale
Common Stock
2021-08-20$8.79/sh−4,000$35,142→ 41,485 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock option is fully vested and exercisable.